How does Cagrilintide work?
Long-acting amylin agonist. Binds amylin receptors (also calcitonin receptor crosstalk) to slow gastric emptying and increase satiety through a different pathway than GLP-1. Pairs naturally with Semaglutide as 'CagriSema.' In plain terms, Cagrilintide is an appetite-control shot for weight loss. A long-acting amylin agonist that works on a different pathway than the GLP-1 drugs, often paired with Semaglutide as 'CagriSema' to break GLP-1 plateaus. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Users plateaued on Semaglutide or Tirzepatide
- People wanting cleaner satiety without bigger GLP-1 nausea
- Combination-therapy stacks under provider guidance
References
- Once-weekly cagrilintide for weight management, Phase 2 trial — Lau DCW et al., Lancet, 2021
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) — Garvey et al., N Engl J Med, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial — Enebo et al., Lancet, 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Cagrilintide
Last updated 2026-06-06.